efficacy of semaglutide and tirzepatide in reducing liver fat Incretin-based therapies for the treatment obesity-related diseases Synergistic mechanisms of tirzepatide and

Abdel-Mottaleb, M

Julie E

Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL

The DIAZOB primary care diabetes study

This protocol uses lower initial doses of compounded semaglutide designed to reduce nausea and other side effects while still engaging your appetite-regulation pathways

Important safety considerations for tirzepatide include its boxed warning for thyroid C-cell tumors (contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), risk of pancreatitis, gallbladder disease, and potential complications in patients with diabetic retinopathy